Clinical Trial Update: A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of Pelcitoclax (APG-1252) for Neuroendocrine Tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Pelcitoclax (APG-1252) (Pelcitoclax)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Neuroendocrine Tumors | Phase 1 | Status: TERMINATED